Peptide therapies · Mixed evidence by peptide · Mostly off-label
Peptides for Erectile Dysfunction
& Sexual Performance, Honestly Assessed
“Peptide therapy” covers a wide range of compounds with very different levels of evidence behind them. Some, like PT-141, have real completed human trials (though not in men specifically, at the FDA-approval level). Others, like BPC-157 and TB-500, have far more limited human data. This page separates what’s actually been studied from what’s still speculative.
None of the peptides discussed on this page are FDA-approved specifically for male sexual performance or erectile dysfunction. All use for these purposes is off-label or via compounding pharmacies.
The best-studied option
PT-141 (Bremelanotide)
A melanocortin receptor agonist that works on the brain’s desire and arousal pathways rather than blood flow — with real Phase II trial data in men, though no FDA approval for male use.
Other peptides discussed for sexual health
Where the rest of the peptide landscape fits in
These work through entirely different mechanisms than PT-141 — supporting tissue, vascular, and hormonal health rather than acting directly on arousal.
BPC-157 & TB-500
A regenerative peptide stack studied for tissue repair and vascular support rather than direct arousal effects. Evidence is more limited than PT-141’s, with most human data coming from a single small pilot study rather than controlled trials.
Hormonal pathway · Emerging researchKisspeptin
A peptide involved in regulating the hypothalamic-pituitary-gonadal axis — the hormonal signaling chain behind testosterone production and sexual response. Discussed for hormonal optimization and sexual health support.
Systemic · Not sexual-health-specificOxytocin & GH-Releasing Peptides
Oxytocin is linked to bonding and orgasm intensity; growth hormone-releasing peptides are discussed for broader recovery and body composition goals, with secondary interest in sexual health. Neither is a direct erectile function treatment.
How the evidence compares
PT-141 vs. BPC-157/TB-500 vs. PDE5 inhibitors
| Feature | PT-141 | BPC-157 / TB-500 | Viagra® / Cialis® |
|---|---|---|---|
| Mechanism | Central — brain desire/arousal pathway | Systemic vascular/tissue support | Peripheral — blood flow |
| FDA-approved for men? | No | No | Yes |
| Human trial evidence | Phase II RCT completed in men | One small pilot study | Extensive, decades of trials |
| Best fit | Low desire, or ED unresponsive to PDE5i | Supportive/adjunct to other treatments | First-line ED treatment |
Common questions
Frequently asked questions
Is PT-141 FDA-approved for men?
No. Bremelanotide is FDA-approved only as Vyleesi® for hypoactive sexual desire disorder in premenopausal women. There is no approved product for men — any male use is off-label, typically via compounded formulations from licensed compounding pharmacies.
How is PT-141 different from Viagra or Cialis?
PDE5 inhibitors work peripherally, increasing blood flow to the penis but requiring arousal to already be present. PT-141 works centrally on the brain’s desire and arousal pathways, which is why it’s discussed both for low libido and for ED — particularly in men whose ED doesn’t respond well to PDE5 inhibitors alone.
Can PT-141 be combined with Viagra or Cialis?
A published study found bremelanotide combined with sildenafil produced significantly better erectile response than sildenafil alone in men who hadn’t responded well to sildenafil by itself. This combination is discussed clinically for PDE5-inhibitor non-responders, though it should be managed by a physician familiar with both medications.
Are BPC-157 and TB-500 the same kind of peptide as PT-141?
No. PT-141 acts directly on brain arousal pathways. BPC-157 and TB-500 are discussed for systemic tissue and vascular support rather than direct arousal effects, and have a smaller human evidence base — mainly one small pilot study rather than a completed randomized trial. See our dedicated BPC-157 & TB-500 page for the full evidence picture, including current regulatory status.
Considering peptide therapy?
Given how much regulatory status and evidence quality varies between peptides, a detailed conversation with a specialist is essential. Search our directory or ask in the forum first.
Key sources: FDA prescribing information for VYLEESI (bremelanotide), NDA 210557 · Diamond & Molinoff et al., published Phase II trial data on bremelanotide for male erectile dysfunction · PhallusMD’s BPC-157 & TB-500 page for that evidence base
This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. No peptide discussed on this page is FDA-approved for male sexual performance or erectile dysfunction. All use for these purposes is off-label or via compounded formulations. Always consult a licensed physician before pursuing any treatment. Vyleesi® is a registered trademark of Palatin Technologies.